Related references
Note: Only part of the references are listed.Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder
Barbara King et al.
EXPERIMENTAL NEUROLOGY (2016)
Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA
Barbara King et al.
JOURNAL OF NEUROCHEMISTRY (2016)
A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA
Simon A. Jones et al.
MOLECULAR GENETICS AND METABOLISM (2016)
Delivery of therapeutic protein for prevention of neurodegenerative changes: Comparison of different CSF-delivery methods
Neil R. Marshall et al.
EXPERIMENTAL NEUROLOGY (2015)
Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice
Helen Beard et al.
MOLECULAR GENETICS AND METABOLISM (2015)
Improvement of CNS Defects Via Continuous Intrathecal Enzyme Replacement by Osmotic Pump in Mucopolysaccharidosis Type II Mice
Young Bae Sohn et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2013)
An In Vivo Canine Study to Assess Granulomatous Responses in the MedStream Programmable Infusion SystemTM and the SynchroMed II Infusion System®
Aileen Michael et al.
PAIN MEDICINE (2012)
CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
Pericles Calias et al.
PLOS ONE (2012)
Intrathecal Enzyme Replacement Therapy for Mucopolysaccharidosis I: Translating Success in Animal Models to Patients
Patricia I. Dickson et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)
Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy
Stijn Stroobants et al.
HUMAN MOLECULAR GENETICS (2011)
Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump
Adam M. Sonabend et al.
NEURO-ONCOLOGY (2011)
Enzyme replacement reduces neuropathology in MPS IIIA dogs
Allison C. Crawley et al.
NEUROBIOLOGY OF DISEASE (2011)
Mucopolysaccharidosis Type IIIA: Clinical Spectrum and Genotype-Phenotype Correlations
Marlies J. Valstar et al.
ANNALS OF NEUROLOGY (2010)
Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease
James C. Dodge et al.
EXPERIMENTAL NEUROLOGY (2009)
Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs-A proof of principle study
Kim M. Hemsley et al.
MOLECULAR GENETICS AND METABOLISM (2009)
Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice
K. M. Hemsley et al.
GENES BRAIN AND BEHAVIOR (2008)
Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis
Michael Chang et al.
MOLECULAR THERAPY (2008)
Pathology of mucopolysaccharidosis IIIA in huntaway dogs
R. D. Jolly et al.
VETERINARY PATHOLOGY (2007)
Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA
Allison C. Crawley et al.
BRAIN RESEARCH (2006)
Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I
E Kakkis et al.
MOLECULAR GENETICS AND METABOLISM (2004)
Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs
G Yogalingam et al.
GENOMICS (2002)
Mucopolysaccharidosis IIIA (Sanfilippo syndrome) in a New Zealand Huntaway dog with ataxia
RD Jolly et al.
NEW ZEALAND VETERINARY JOURNAL (2000)
Share Paper
